Enliven Therapeutics (ELVN) AI Stock Analysis

• Market Cap: $2.32B
• Dividend Yield: N/A
• Average Volume (3M): 1.33M
• Price to Earnings (P/E): ―
• Beta (1Y): 0.94
• Revenue Growth: N/A
• EPS Growth: 3.18%
• Country: US
• Employees: 62
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.48
• Shares Outstanding: 59,800,407
• 10 Day Avg. Volume: 2,004,261
• 30 Day Avg. Volume: 1,328,069
• PEG Ratio: 2.65
• Price to Book (P/B): 1.90
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -12.38
• Enterprise Value/Market Cap: 0.96
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: -48.34K
• Enterprise Value/Ebitda: -19.43
• 1Y Price Target: $47.60
• Price Target Upside: 22.59% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 6
• EPS Forecast (FY): -2.1
• Revenue Forecast (FY): $10.00K

• Rating: 56 Neutral
• Price Target: $40.00 ▲(3.01% Upside)
• Action: Reiterated Date: 03/27/26
• Date: Action: Reiterated 03/27/26

The score is primarily held back by weak income statement and cash flow fundamentals (no revenue, widening losses, and significant cash burn) despite a strong, low-debt balance sheet. Technicals are supportive due to a strong uptrend, but overbought signals add near-term risk. Valuation support is limited by negative earnings and no dividend, while the recent board appointment is a modest positive catalyst.

Positive Factors

Balance sheet strength

A virtually debt-free balance sheet with materially higher equity and assets provides durable financial flexibility for a pre-revenue biotech. This reduces default risk, supports multi-stage clinical funding needs, and lengthens time the company can advance ELVN-001 before needing urgent external financing.

Negative Factors

No revenue

Operating without product revenues leaves the company dependent on financing to fund development. Over a 2–6 month horizon, lack of revenue sustains uncertainty about commercialization timing and increases reliance on capital markets to bridge clinical and regulatory milestones.

Enliven Therapeutics Business Overview & Revenue Model

Company Description

Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its pipeline of small molecule kinase inhibitors include ELVN-001, which is...

Read more

Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its pipeline of small molecule kinase inhibitors include ELVN-001, which is...

How the Company Makes Money

null...

Enliven Therapeutics Financial Statement Overview

Breakdown	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00
Gross Profit	-263.00K	0.00	0.00	0.00	0.00
EBITDA	-119.39M	-104.24M	-83.23M	-38.58M	-24.65M
Net Income	-103.69M	-89.02M	-71.58M	-37.66M	-24.74M
Balance Sheet
Total Assets	476.17M	325.76M	271.87M	83.30M	113.33M
Cash, Cash Equivalents and Short-Term Investments	462.62M	313.44M	253.15M	75.54M	110.02M
Total Debt	399.00K	0.00	335.00K	323.00K	159.00K
Total Liabilities	16.68M	15.91M	25.96M	160.12M	6.47M
Stockholders Equity	459.60M	309.85M	245.91M	-76.83M	106.86M
Cash Flow
Free Cash Flow	-70.46M	-73.24M	-61.42M	-32.69M	-19.32M
Operating Cash Flow	-70.30M	-73.19M	-61.27M	-32.08M	-19.13M
Investing Cash Flow	-173.84M	-36.00M	-148.41M	-612.00K	-191.00K
Financing Cash Flow	218.87M	133.16M	234.29M	-1.80M	-1.02M

Enliven Therapeutics Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 38.83
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ELVN, the sentiment is Positive. The current price of 38.83 is above the 20-day moving average (MA) of 32.31, above the 50-day MA of 29.46, and above the 200-day MA of 22.61, indicating a bullish trend. The MACD of 2.85 indicates Negative momentum. The RSI at 67.83 is Neutral, neither overbought nor oversold. The STOCH value of 83.62 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ELVN.

Enliven Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ELVN	56 Neutral	$2.32B	-8.42	-24.22%	―	―	3.18%
NTLA	56 Neutral	$1.55B	-2.54	-56.63%	―	33.52%	21.66%
VRDN	54 Neutral	$1.93B	-5.48	-58.44%	―	23340.07%	18.06%
SRPT	53 Neutral	$2.44B	-3.16	-57.52%	―	47.15%	-311.26%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
ABCL	49 Neutral	$1.07B	-6.98	-14.16%	―	7.16%	3.95%

Enliven Therapeutics Corporate Events